# Changes of circulating biomarkers of inflammation and glycolipid metabolism by CPAP in OSA patients: a meta-analysis of time-dependent profiles

# Yi Wang\*, Ying Ni Lin\*, Li Yue Zhang\*, Chuan Xiang Li, Shi Qi Li, Hong Peng Li, Liu Zhang, Ning Li, Ya Ru Yan and Qing Yun Li

### Abstract

**Background:** Continuous positive airway pressure (CPAP) is the first-line therapy for moderate-to-severe obstructive sleep apnea (OSA). Specifying timing of CPAP benefits on OSA-related biomarkers will help to assess the effectiveness of CPAP and to optimize the treatment strategies.

**Purpose:** To explore the time-dependent changes of circulating biomarkers to CPAP treatment in patients with OSA, including inflammatory biomarkers [C-reactive protein (CRP) and tumor necrosis factor– $\alpha$  (TNF- $\alpha$ )] and glycolipid metabolic biomarkers [fasting blood glucose (FBG), fasting insulin (FINS), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), and triglyceride (TG)].

**Methods:** Searches of PubMed and Embase database were completed. Two independent reviewers extracted data from 68 included studies. A meta-analysis was conducted using a random-effect (or fixed-effect) model and standardized mean difference (SMD) model. The timing profiles of circulating biomarkers changes of inflammation and glycolipid metabolism were analyzed based on different CPAP duration, that is, short-term (<3 months), mid-term (3-6 months), and long-term (>6 months).

**Results:** Those first improved by short-term treatment include CRP [SMD: 0.73, 95% confidence interval (CI): 0.15–1.31; p = 0.014], TNF- $\alpha$  [SMD: 0.48 (95% CI: 0.10–0.86; p = 0.014]], FBG [SMD: 0.32 (95% CI: 0.07–0.57; p = 0.011)], and LDL [SMD: 0.40 (95% CI: 0.18–0.62; p = 0.000]]. Those first improved by the mid-term or long-term treatment include HDL [SMD: -0.20 (95% CI: -0.36 to -0.03; p = 0.018]] and TC [SMD: 0.20 (95% CI: 0.05–0.34; p = 0.007]]. There were insignificant changes for TG and FINS after short or long CPAP.

**Conclusion:** Our results imply that changes of circulating biomarkers for patients with OSA under CPAP treatment have a time-dependent profile.

*Keywords:* circulating biomarkers, continuous positive airway pressure, obstructive sleep apnea, phase-specific effectiveness

Received: 11 July 2021; revised manuscript accepted: 16 December 2021.

### Introduction

Obstructive sleep apnea (OSA), characterized by repetitive overnight hypoxic episodes and subsequent sleep fragmentation due to a complete or partial collapse of the upper airway, has become a global health burden. It is estimated that 936 million adults worldwide aged 30–69 years suffer from OSA, among whom 425 million suffer from moderate-to-severe OSA.<sup>1</sup> Observational studies have linked OSA with an increased risk of insulin Ther Adv Chronic Dis

2022, Vol. 13: 1–15 DOI: 10.1177/ 20406223221070919

© The Author(s), 2022. Article reuse guidelines: sagepub.com/journalspermissions

Correspondence to: Qing Yun Li

Department of Respiratory and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, No. 197 Rui Jin 2nd Road, Shanghai 200025, P.R. China Institute of Respiratory Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China Liqingyun68/Ghotmail.com Yi Wang

Ying Ni Lin Li Yue Zhang Shi Qi Li Hong Peng Li Liu Zhang Ning Li Ya Ru Yan

Department of Respiratory and Critical Care Medicine, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, P.R. China Institute of Respiratory Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China

#### Chuan Xiang Li

Department of Respiratory and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China Institute of Respiratory Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China Department of Respiratory and Critical Care Medicine, Tongren Hospital Affiliated to Wuhan University, The Third Hospital of Wuhan, Wuhan, P.R. China \*Co-first authors and

\*Co-first authors and equally contributed to this work.

journals.sagepub.com/home/taj



resistance, dyslipidemia, and cardiovascular diseases, and an enhanced mortality from COVID-19,<sup>2-5</sup> which could be ascribed to oxidative stress and systemic inflammation.6,7 Targeting OSA may reduce the systemic inflammation, and improve the clinical outcomes. Continuous positive airway pressure (CPAP) has been the firstline therapy for moderate-to-severe OSA. It offers continuous positive pressure to prevent the occurrence of airway collapse and hypoxia and sleep fragmentation so as to ablate apneas in sleep and increase oxygen saturation and sleep quality. During the past two decades, circulating inflammatory and metabolic biomarkers including C-reactive protein (CRP), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), fasting blood glucose (FBG), fasting insulin (FINS), and lipid profiles, which are important predictors for OSA-related cardiometabolic risk, have been widely explored for the evaluation of the role of CPAP treatment,8-15 but the results have not always coincided. It might be explained by different CPAP treatment duration. Therefore, we proposed that the choice of biomarkers for the evaluation should be based on the time-response characteristics of them.<sup>16</sup>

Several studies have demonstrated that benefits of CPAP on biomarkers have time-related profiles. For example, Mermigkis et al.<sup>17</sup> reported a gradual decrease in CRP after 3 months of CPAP treatment, and a sharp drop after 6 months and reached a plateau after this time point. Simon et al.<sup>18</sup> found that 2-month CPAP therapy resulted in a significant decrease of both total cholesterol (TC) and low-density lipoprotein (LDL) levels compared with baseline values, and the effect was maintained after 6 months and 5 years of treatment, but no significant change in serum triglycerides (TG) or high-density lipoprotein (HDL) after 2 months, 6 months, and 5 years of CPAP treatment. Till now, current evidence is not conclusive about the time-dependent profiles of the various biomarkers in response to CPAP treatment. This present meta-analysis will provide some evidence for this issue.

## Methods

### Literature search process

PRISMA guidelines were followed to perform literature search.<sup>19</sup> PICOS format was followed; P: glycolipid metabolic and inflammatory biomarkers (CRP; TNF-α; FBG; FINS; LDL; HDL; TC; and TG), I: CPAP treatment, C: levels of biomarkers before and after treatment, O: improvement in biomarker levels. A comprehensive literature search was performed using the PubMed and Embase databases by using the following words: [(obstructive sleep apnea or sleep disorder breathing or obstructive sleep apnea hypopnea syndromes) and (continuous positive airway pressure or continuous positive pressure ventilation) and (markers or C-reactive protein or tumor necrosis factor- $\alpha$  or fasting blood glucose or insulin or low-density lipoprotein or high-density lipoprotein or cholesterol or triglyceride)].

### Study selection

The inclusion and exclusion criteria were as follows: (1) studies written in English; (2) studies published between January 2000 and October, 2020; (3) studies performed on adults (>18 years old); (4) full-text manuscripts and quantitative data from before and after prospective CPAP intervention available; (5) studies evaluating the effects of CPAP withdrawal on sleep and physiology were excluded; (6) OSA was strictly defined as an apnea-hypopnea index  $(AHI) \ge 5$  events/h measured by polysomnography (PSG) or portable devices; (7) all the biomarker samples were derived from fasting blood in the morning; (8) studies using bilevel positive airway pressure and other positive airway pressure treatment were also included; (9) studies with identical data sets or the same study subjects were excluded; and (10) data from patients with poor adherence when reported by the manuscript were excluded. During the process of study selection, we found that there was limited available evidence from randomized controlled trials to analyze the timedependent profile of the eight biomarkers. And to guarantee a homogeneity of research methods, we included before-and-after self-controlled studies in the meta-analysis. In addition, case reports, conference abstracts, and comments were not reviewed. Two investigators reviewed the titles, abstracts, and the full texts of the selected studies (Figure 1).

### Quality assessment and data extraction

Study quality was assessed using the methodological index for nonrandomized studies (MINORS) which includes 12 items with the first 8 being specifically for noncomparative studies.<sup>20</sup> The items are scored 0 (not reported), 1 (reported



Figure 1. Literature search process.

but inadequate) or 2 (reported and adequate). The global ideal score is 16 for noncomparative studies. A score of  $\leq 8$  was considered poor quality, 9–14 moderate quality, and  $\geq 15$  good quality for noncomparative studies.<sup>21</sup> The assessment of study quality was carried out by two independent investigators, and conflicting assessments were resolved by consensus with a third investigator.

The baseline characteristics of the included patients and quality score of each study were documented (Supplementary Table 1). We calculated estimated mean and standard deviation (SD) for each biomarker showed in median and interquartile ranges or ranges with the method reported in the publications,<sup>22,23</sup> and to reduce error, data which were skewed significantly away from normality cannot be transformed into mean and SDs according to method by Shi *et al.*<sup>24</sup> If data were reported in mean and standard error (SE), then SD would be calculated by multiplying SE by square root of the number of patients.

### Statistical analysis

Meta-analysis was completed using Stata statistical software (Version 14.0; Stata Corporation, College Station, TX, USA), which was combined using a random-effect (or fixed-effect) model and standardized mean difference (SMD) meta-analysis model. The heterogeneity of SMD across studies was evaluated by  $I^2$  and Q statistics. Statistical heterogeneity was defined as an  $I^2$  statistic value  $\geq 50\%$  or p value for heterogeneity ( $p^h$ ) < 0.10. The Galbraith plot was used to detect the possible studies causing heterogeneity. Egger's test was used to examine publication bias. Meta-regression was used to evaluate effect of some confounding factors on CPAP effectiveness on biomarkers. Studies were divided into three subgroups based on the duration of CPAP treatment: short term (<3 months), mid-term ( $\geq 3$  and <6 months), and long term ( $\geq 6$  months).

## Results

A total of 1138 studies were reviewed for inclusion, of which 68 studies were pooled for analysis of different circulating biomarkers, including 34 studies (1385 patients) for CRP, 15 studies (454 patients) for TNF- $\alpha$ , 33 studies (896 patients) for FBG, 22 studies (471 patients) for FINS, 21 studies (670 patients) for LDL, 26 studies (864 patients) for HDL, 28 studies (918 patients) for TC, and 30 studies (1021 patients) for TG.

## Inflammatory biomarkers

- CRP: The overall pooled SMD and its 95% confidence interval (CI) for CRP was calculated to be 0.50 (95% CI: 0.34–0.67, Z=6.08, p=0.000; I<sup>2</sup> = 72.4%, p<sup>h</sup> = 0.000). Subgroup analysis showed that SMDs for the short-term, mid-term, and long-term subgroups were 0.73 (95% CI: 0.15–1.31; p=0.014), 0.50 (95% CI: 0.28–0.73; p=0.000), and 0.40 (95% CI: 0.14–0.67; p=0.003), respectively (Figure 2). Galbraith plot suggested that five studies<sup>17,25–28</sup> may have been the sources of heterogeneity.
- 2. TNF- $\alpha$ : The overall pooled SMD for TNF- $\alpha$  was 0.49 (95% CI: 0.22–0.76, Z=3.61, p=0.000;  $I^2 = 72.3\%$ ,  $p^h = 0.000$ ). Subgroup analysis showed that SMDs for the short-term, mid-term, and long-term subgroups were 0.48 (95% CI: 0.10–0.86; p=0.014), 0.45 (95% CI: -0.15 to 1.05; p=0.140), and 0.60 (95% CI: 0.26–0.94; p=0.001), respectively (Figure 3). Three studies<sup>25,29,30</sup> were found to be potential sources of heterogeneity suggested in the Galbraith plot.

## Fasting glucose and insulin

1. FBG: The overall pooled SMD for FBG was 0.22 (95% CI: 0.10–0.33, Z=3.57, p=0.000;  $I^2 = 34.7\%$ ,  $p^{\rm h} = 0.028$ ). Subgroup analysis showed that SMDs for the short-term, midterm, and long-term subgroups were 0.32

(95% CI: 0.07–0.57; p=0.011), 0.30 (95% CI: 0.14–0.46; p=0.000), and –0.03 (95% CI: –0.19 to 0.14; p=0.736), respectively (Figure 4). Two studies in the short-term<sup>31</sup> and mid-term subgroup,<sup>32(the IGT group)</sup> were found to be potential sources of heterogeneity in the Galbraith plot.

FINS: The overall pooled SMD for FINS was 0.05 (95% CI: -0.07 to 0.18, Z=0.83, p=0.409; I<sup>2</sup> = 0%, p<sup>h</sup> = 0.888). Subgroup analysis showed that SMDs for the short-term, mid-term, and long-term subgroups were 0.16 (95% CI: -0.05 to 0.37; p=0.129), 0.10 (95% CI: -0.13 to 0.34, p=0.392), and -0.11 (95% CI: -0.33 to 0.11, p=0.327), respectively (Figure 5).

### Lipids profiles

- LDL: The overall pooled SMD for LDL was 0.27 (95% CI: 0.16–0.38), Z=4.93, p=0.000; I<sup>2</sup> = 0%, p<sup>h</sup> = 0.878). Subgroup analysis showed that SMDs for the short-term, mid-term, and long-term subgroups were 0.40 (95% CI: 0.18–0.62; p=0.000), 0.19 (95% CI: 0.00–0.39; p=0.050), and 0.25 (95% CI: 0.09–0.41; p=0.002), respectively (Figure 6).
- 2. HDL: The overall pooled SMD for HDL was -0.16 (95% CI: -0.25 to -0.06), Z=3.28, p=0.001;  $I^2 = 0\%$ ,  $p^h = 0.878$ ). Subgroup analysis showed that SMDs for the short-term, mid-term, and long-term subgroups were -0.11 (95% CI: -0.36 to 0.14; p=0.390), -0.20 (95% CI: -0.36 to -0.03; p=0.018), and -0.15 (95% CI: -0.28 to -0.02; p=0.028), respectively (Figure 7). One heterogeneous study<sup>33</sup> in the mid-term subgroup was identified by the Galbraith plot.
- TC: The overall pooled SMD for TC was 0.18 (95% CI: 0.09–0.28, Z=3.89, p=0.000; I<sup>2</sup> = 1.6%, p<sup>h</sup> = 0.441). Subgroup analysis showed that SMDs for the short-term, midterm, and long-term subgroups were 0.23 (95% CI: -0.09 to 0.55; p=0.158), 0.14 (95% CI: -0.01 to 0.30; p=0.069), and 0.20 (95% CI: 0.05–0.34; p=0.007), respectively (Figure 8). The Galbraith plot suggested that two studies<sup>31,34</sup> in the short-term subgroup could have caused heterogeneity.
- 4. TG: The overall pooled SMD for TG was 0.12 (95% CI: 0.03–0.21, Z=2.74,

study	CRP	SMD (95% CI)	% Weight
<3m			
Yokoe T 2003	· · · · · · · · · · · · · · · · · · ·	1 71 (0 92 2 50)	2 19
Dorkova Z 2008		0.54 (-0.17, 1.24)	2.10
Tulmac M 2012		-0.08 (-0.59, 0.42)	3.16
Nural Sh 2013		0.31 (-0.24, 0.87)	2.97
Nural S 2013		0.38 (-0.17, 0.94)	2.96
Wang $\vee$ 2015		<b>2</b> 2 22 (1 51 2 93)	2.30
Spießhöfer J 2017		0.26(-0.32, 0.84)	2.44
Subtotal (Leaguared = $84.0\%$ , p = 0.000)		0.73 (0.15, 1.31)	19.06
		0.70 (0.10, 1.01)	10.00
3m~6m			
Patruno, Vb 2007	••••	0.55 (-0.18, 1.28)	2.38
Patruno, V 2007	•	1.08 (0.34, 1.83)	2.33
lesato, K 2007	<b>→</b>	0.37 (-0.10, 0.84)	3.32
Carneiro, G 2009		-0.07 (-1.12, 0.98)	1.58
Shilna,K 2010		0.25 (-0.14, 0.64)	3.60
Chung, S 2011		0.23 (-0.34, 0.79)	2.93
Panoutsopoulos, A 2012		1.03 (0.23, 1.82)	2.19
Zhao, Q 2012	•••	0.63 (0.08, 1.17)	3.01
Salord, N 2013		0.10 (-0.50, 0.71)	2.80
Kallianos, A 2015	<u>+ + </u>	0.34 (-0.10, 0.79)	3.41
Mysliwiec, V 2015		0.01 (-0.58, 0.60)	2.85
Azuma,M 2015	•	0.40 (-0.02, 0.82)	3.49
Can, M 2016	• <u>•</u>	1.12 (0.50, 1.74)	2.73
Jin, F 2017	· •	1.34 (1.04, 1.65)	3.92
Binar, M 2017	•	0.53 (-0.00, 1.07)	3.06
Xu, Q 2017		0.27 (-0.33, 0.86)	2.84
Özdemir, C 2019		0.18 (-0.34, 0.69)	3.13
Subtotal (I-squared = 66.1%, p = 0.000)		0.50 (0.28, 0.73)	49.56
≥6m			
Steiropoulos, P 2007		0.46 (-0.17, 1.09)	2.71
Ishida, K 2009		0.31 (-0.13, 0.75)	3.42
Nena, E 2010	<b>→</b>	0.15 (-0.25, 0.56)	3.56
Nena, Eb 2010		0.13 (-0.59, 0.85)	2.42
Kato, M 2011		0.13 (-0.37, 0.64)	3.16
Colish, J 2012		0.33 (-0.07, 0.74)	3.55
Mermigkis, C 2012		0.91 (0.77, 1.05)	4.41
Monneret, D 2016		0.33 (-0.20, 0.86)	3.08
Ye, L 2018		0.93 (-0.00, 1.85)	1.84
Simon, B 2020		0.33 (-0.16, 0.82)	3.24
Subtotal (I-squared = 73.0%, p = 0.000)	$\diamond$	0.40 (0.14, 0.67)	31.39
Overall (I-squared = 72.4%, p = 0.000)		0.50 (0.34, 0.67)	100.00
NOTE: Weights are from random effects analysis			
-2.93	0 2	2.93	



 $p=0.006; I^2 = 0\%, p^h = 1.000$ ). Subgroup analysis showed that SMDs for the shortterm, mid-term, and long-term subgroups were 0.17 (95% CI: -0.02 to 0.37, p=0.084), 0.11 (95% CI: -0.05 to 0.26; p=0.179), and 0.11 (95% CI: -0.01 to 0.24; p=0.081), respectively (Figure 9).

In summary, modest reductions in CRP, TNF- $\alpha$ , FBG, and LDL resulting from CPAP occurred in the early phase of treatment while marginal decreases in HDL and TC were only observed

after mid and long duration of CPAP treatment. Besides, no significant changes were found in FINS and TG at any time point (Figure 10).

## Heterogeneity, quality score, and publication bias

The influence of heterogeneity on our results should be taken into consideration. Most of the heterogeneous studies<sup>17,25,26,28,29,31–34</sup> had positive results. Two of the included studies were with low quality,<sup>35,36</sup> and the rest were with moderate

Study ID	TNF-α	SMD (95% CI)	% Weight
<3m Minoguchi, K 2004		- 0.77 (-0.06, 1.60)	5.03
Rvan. S 2006		0.55 (0.15, 0.96)	8.00
Dorkova, Z 2008		0.40 (-0.30, 1.10)	5.86
Li, Y 2008		1.62 (1.06, 2.17)	6.86
Nural, S 2013		0.03 (-0.53, 0.58)	6.89
Nural, Sb 2013		0.03 (-0.52, 0.59)	6.89
Yoshikawa, M 2014		0.44 (-0.16, 1.04)	6.57
Borges, Y.G 2020 -		0.00 (-0.65, 0.65)	6.18
Subtotal (I-squared = 70.5%, p = 0.001)		0.48 (0.10, 0.86)	52.28
3m~6m Vgontzas, A.N 2008 Carneiro, G 2009 Ünüvar Doğan, F 2014 Karamanlı, H 2014 Jin, F 2017 Subtotal (I-squared = 83.9%, p = 0.000)		-0.08 (-0.78, 0.61) 0.67 (-0.41, 1.75) 0.40 (-0.13, 0.94) 0.01 (-0.46, 0.48) 1.20 (0.90, 1.50) 0.45 (-0.15, 1.05)	5.91 3.77 7.00 7.52 8.70 32.90
≥6m			
Steiropoulos, P2 2009		0.51 (0.01, 1.00)	7.31
Vicente, E 2016		0.69 (0.22, 1.16)	7.52
Subtotal (I-squared = $0.0\%$ , p = $0.602$ )	$\Leftrightarrow$	0.60 (0.26, 0.94)	14.82
Overall (I-squared = 72.3%, p = 0.000) NOTE: Weights are from random effects an	nalysis	0.49 (0.22, 0.76)	100.00
-2.17	0	2.17	
	-		

**Figure 3.** Forest plot for TNF- $\alpha$ .

quality (Supplementary Table 1). The Egger's test showed that there existed significant publication bias for CRP (short-term subgroup,  $P^{\text{bias}} = 0.019$ ; long-term subgroup,  $P^{\text{bias}} = 0.047$ ) and FBG (mid-term subgroup,  $P^{\text{bias}} = 0.014$ ). After removing the heterogeneous and low-quality studies, the bias was still there only for FBG. Nevertheless, the effect of heterogeneity on the time-dependent profile of changes in those biomarkers is tiny if the heterogeneous and low-quality studies were removed.

### Meta-regression

Meta-regression was performed to evaluate the effect of age, body mass index (BMI), AHI, and baseline biomarkers levels on the CPAP effectiveness on each biomarker. AHI, BMI, and age do not affect the changes of all biomarkers before and after CPAP treatment. Only baseline level of FBG (p=0.000) and TNF- $\alpha$  (p=0.003) was found to have significant effect on improvement of these two biomarkers after treatment.

### Discussion

OSA is a long-lasting condition with early repeated oxidative stress injury and pro-inflammatory releases, and several late cardiovascular diseases and other complications. The direct consequence of chronic intermittent hypoxia (CIH) is an oxidative imbalance, with reactive oxygen species production and the inflammatory cascade's activation with pro-inflammatory cytokines releases.<sup>37</sup> These products then, interacting with other factors such as sympathetic activation, cause subclinical target organ damage, including cardiac function and metabolic health.<sup>38</sup> Compared with the early effect of CPAP on improving respiratory events and davtime

Study			%
ID	FBG	SMD (95% CI)	Weight
10.12			
<3m Dorkova Z 2008	i 👘	0.53 (-0.17, 1.24)	2 14
Dukova, 2 2008		0.35 (-0.17, 1.24)	2.14
Akingusi M 2011		0.29 (-0.21, 0.79)	3.45
Akililiusi, M 2011		0.08 (0.42, 0.50)	3.73
Babulao, A 2014 Kanimazhi S 2015		0.00 (-0.42, 0.39)	3.40
			2.59
Guo, L.A. 2015		- 1.21 (0.73, 1.69)	3.05
Fall, 2 2010 Makhlani, B 2017		0.11 (-0.31, 0.73)	2.59
		0.34 (-0.27, 1.36)	1.70
		0.23 (-0.39, 0.86)	2.56
Asgan, A 2019		0.09 (-0.37, 0.56)	3.73
Subtotal (I-squared = $48.9\%$ , p = $0.040$ )		0.32 (0.07, 0.57)	29.57
3m~6m			
Vgontzas, A.N 2008		0.18 (-0.52, 0.87)	2.19
Henley, D.E 2009	• • • • • • • • • • • • • • • • • • •	0.65 (-0.09, 1.38)	2.01
Shilna,K 2010	<b>.</b>	0.04 (-0.35, 0.43)	4.53
Chung, S 2011		0.20 (-0.36, 0.77)	2.93
Oyama, J 2012	••••	0.47 (-0.03, 0.97)	3.48
Yang, D 2013		0.31 (-0.28, 0.91)	2.75
Zhang, X.B 2014		0.12 (-0.32, 0.57)	3.97
Kallianos, A 2015		0.26 (-0.18, 0.70)	4.01
Kostopoulos, K 2016		0.30 (-0.26, 0.86)	3.00
Mineiro, M.A 2017		0.04 (-0.43, 0.52)	3.67
Thorn, C.E 2017		0.00 (-0.84, 0.84)	1.64
Gong, L.Jb 2020	T !	→ 1.42 (0.55, 2.29)	1.54
Gong, L.Jc 2020		0.71 (-0.03, 1.45)	1.99
Gona, L.J 2020		0.70 (0.06, 1.34)	2.48
Subtotal (I-squared = 10.7%, p = 0.336)		0.30 (0.14, 0.46)	40.20
≥6m Steiropoulos P.2009		-0 15 (-0 75 0 46)	2.68
Ishida K 2009		-0.13 (-0.57, 0.30)	4.03
Nona E 2010			4.00
Nena, E 2010		-0.24 (-0.04, 0.17)	4.30
Parcelá A 2014		-0.49 (-1.22, 0.24)	2.04
Managarat D 2016		0.07 (-0.32, 0.46)	4.00
Falisiana A 2017		-0.07 (-0.60, 0.45)	3.20
Feliciano, A 2017		0.03 (-0.56, 0.82)	2.77
Feliciano, AD 2017		0.29 (-0.28, 0.86)	2.92
Simon, B 2020		0.29 (-0.19, 0.78)	3.58
Subtotal (I-squared = 0.0%, p = 0.638)		-0.03 (-0.19, 0.14)	30.24
Overall (I-squared = 34.7%, p = 0.028)	<b>\$</b>	0.22 (0.10, 0.33)	100.00
NOTE: Weights are from random effects analysis			
<b>I</b> -2.29	<b>I</b> 0	<b>I</b> 2.29	

Figure 4. Forest plot for FBG.

sleepiness, improvement of different biomarkers by OSA treatment may show a time-dependent profile.<sup>16</sup> However, how long it takes for CPAP to improve inflammatory and glycolipid metabolic biomarkers remains controversial. In this work, we tried to figure out the duration-different changes in the common inflammatory and glycolipid metabolic biomarkers before and after CPAP treatment. Our results indicated that the timing of CPAP benefits differs among different circulating biomarkers. CRP and TNF- $\alpha$  were shown to have an early response to short-term CPAP. Increasing evidence suggests OSA should be viewed as low-grade chronic inflammatory disease.<sup>6</sup> The inflammatory cytokines growth was a direct consequence of intermittent hypoxia by activating nuclear factor– kappa *B* (NF- $\kappa$ B), the master transcriptional regulator of inflammatory responses.<sup>38</sup> The results proved that a significant change of those biomarkers after short-term CPAP can be predicted. Besides, meta-regression suggested that, with

Study ID	FINS	SMD (95% CI)	% Weight
<3m Czupryniak, L 2005 Dorkova, Z 2008 Çuhadaroğlu, Ç 2009 Baburao, A 2014 Kanimozhi, S 2015 Guo, L.X 2015 Pan, Z 2016 Mokhlesi, B 2017 – Subtotal (I-squared = 0.0%, p = 0.764)		-0.30 (-1.23, 0.63) 0.47 (-0.24, 1.17) -0.05 (-0.55, 0.44) 0.13 (-0.38, 0.63) 0.14 (-0.48, 0.76) 0.14 (-0.30, 0.58) 0.59 (-0.05, 1.22) 0.17 (-0.63, 0.97) 0.16 (-0.05, 0.37)	1.90 3.33 6.63 6.41 4.27 8.54 4.09 2.56 37.73
3m~6m Vgontzas, A.N 2008 Henley, D.E 2009 Chung, S 2011 Yang, D 2013 Thorn, C.E 2017 Gong, L.J 2020 Gong, L.Jc 2020 Gong, L.Jc 2020 Subtotal (I-squared = 0.0%, p = 0.793)		-0.05 (-0.75, 0.64) 0.35 (-0.37, 1.07) -0.35 (-0.92, 0.22) 0.28 (-0.31, 0.88) 0.13 (-0.71, 0.96) 0.14 (-0.48, 0.77) 0.29 (-0.48, 1.06) 0.27 (-0.45, 0.99) 0.10 (-0.13, 0.34)	3.42 3.16 5.05 4.66 2.35 4.27 2.75 3.18 28.85
≥6m Steiropoulos, P 2009 Nena, Eb 2010 Nena, E 2010 Monneret, D 2016 Feliciano, A 2017 Feliciano, Ab 2017 Subtotal (I-squared = $0.0\%$ , p = $0.820$ ) Overall (I-squared = $0.0\%$ , p = $0.888$ )		-0.22 (-0.83, 0.38) -0.08 (-0.79, 0.64) 0.12 (-0.29, 0.52) -0.18 (-0.71, 0.34) -0.15 (-0.74, 0.45) -0.37 (-0.94, 0.21) -0.11 (-0.33, 0.11)	4.47 3.21 10.04 5.97 4.70 5.05 33.42
-1.23	0	1.23	

Figure 5. Forest plot for FINS.

baseline serum level ranging from 0.13 to 124.5 pg/ ml, TNF- $\alpha$  in higher levels showed more reduction. Several studies demonstrated that patients with moderate-to-severe OSA showed higher level of TNF- $\alpha$  than those with mild OSA, obese control subjects, and healthy controls.<sup>39,40</sup> Changes in AHI, the percentage of time with oxygen saturation (SpO<sub>2</sub>) < 90%, and mean SpO<sub>2</sub> after treatment with CPAP were correlated with changes in serum levels of TNF- $\alpha$ .<sup>39,41</sup> We did not identify a correlation between baseline AHI and the reduction of TNF- $\alpha$  in meta-regression. Therefore, it is presumable that a change of AHI or SpO<sub>2</sub>, but not the baseline AHI, is associated with the reduction of TNF- $\alpha$  after CPAP treatment. However, we were unable to conduct a meta-regression to evaluate correlation between the change of AHI and  $SpO_2$  and the reduction of the eight biomarkers due to the missing value of post-CPAP polysomnographic parameters in many studies we analyzed.

Short-term CPAP usage significantly decreases serum levels of FBG while FINS remain unchanged after different duration of CPAP. CIH leads to several glucose metabolism alterations, including higher fasting glucose and insulin levels, insulin resistance, glucose intolerance, and  $\beta$ -cell dysfunction. Moreover, intermittent hypoxia-induced sympathetic excitation also

Sime Subtotal (1-squared = 0.0%, p = 0.587) Subtotal (1-squared = 0.0%, p = 0.627) Sime Subtotal (1-squared = 0.0%, p = 0.878)	Study ID	LDL	SMD (95% CI)	% Weight
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	<3m Dorkova, Z 2008 Çuhadaroğlu, Ç 2009 Guo, L.X 2015 Kanimozhi, S 2015 Pan, Z 2016 Asgari, A 2019 Subtotal (I-squared = 0.0%, p = 0.587)		0.39 (-0.31, 1.09) 0.40 (-0.10, 0.91) 0.70 (0.25, 1.15) -0.05 (-0.67, 0.57) 0.36 (-0.27, 0.98) 0.38 (-0.09, 0.85) 0.40 (0.18, 0.62)	2.37 4.60 5.70 3.03 2.98 5.20 23.88
≥6m Börgel, J 2006 Steiropoulos, P 2007 Nena, Eb 2010 Nena, E 2010 Kawano, Y 2012 Monneret, D 2016 Feliciano, A 2017 Simon, B 2020 Overall (I-squared = 0.0%, p = 0.878) $O_{27}(0.16, 0.38)$ 100.00 $O_{27}(0.16, 0.38)$ 100.00	3m~6m         Henley, D.E 2009         Oyama, J 2012         Zhang, X.B 2014         Kallianos, A 2015         Azuma,M 2015         Mineiro, M.A 2017         Subtotal (I-squared = 0.0%, p = 0.961)		0.00 (-0.72, 0.72) 0.24 (-0.25, 0.73) 0.27 (-0.18, 0.71) 0.06 (-0.38, 0.50) 0.20 (-0.22, 0.62) 0.32 (-0.16, 0.79) 0.19 (0.00, 0.39)	2.27 4.81 5.85 6.05 6.63 5.08 30.70
Overall (I-squared = 0.0%, p = 0.878)         0.27 (0.16, 0.38)         100.00           I         I         I	≥6m Börgel, J 2006 Steiropoulos, P 2007 - Nena, Eb 2010 Nena, E 2010 Kawano, Y 2012 - Monneret, D 2016 Feliciano, A 2017 Feliciano, Ab 2017 Simon, B 2020 Subtotal (I-squared = 0.0%, p = 0.627)		0.15 (-0.15, 0.45) 0.38 (-0.25, 1.01) -0.07 (-0.79, 0.64) 0.26 (-0.15, 0.66) 0.24 (-0.27, 0.75) 0.10 (-0.43, 0.62) 0.06 (-0.53, 0.65) 0.57 (-0.02, 1.16) 0.68 (0.19, 1.18) 0.25 (0.09, 0.41)	12.99 2.97 2.27 7.06 4.51 4.23 3.33 3.34 4.71 45.42
-1.18 0 1.18	Uverali (I-squared = 0.0%, p = 0.878)		0.27 (0.16, 0.38)	100.00

Figure 6. Forest plot for LDL.

probably decreases insulin sensitivity, reduces insulin-mediated glucose uptake, and stimulates hepatic gluconeogenesis.38 SMDs of FBG in the short-term and mid-term subgroup were quite different from that of the long-term subgroup. We noticed that the studies<sup>31,32,42,43</sup> in the shortand mid-term treatment subgroups displayed abnormal baseline FBG and showed more reduction in FBG. In the long-term subgroup, FBG was not found to be significantly changed after  $\geq$  6 months of treatment, which might be related to the normal baseline FBG level. The meta-regression analysis also confirmed that baseline FBG played a pivotal role in the effect of CPAP on FBG, which coincides with a previous review that speculated the beneficial effect of CPAP was of larger magnitude in patients with poor glycemic control at baseline.<sup>2</sup> Despite no significant changes of FINS, there is clinical evidence<sup>11,12,14</sup> supporting the effect of CPAP for insulin sensitivity improvement which is also an early response (less than 8 weeks of treatment).<sup>11</sup>

We found that CPAP treatment improves serum levels of cholesterol in OSA patients, which is consistent with a previous meta-analysis.<sup>13</sup> Serum levels of LDL could be decreased within shortterm treatment, and mid-term or long-term CPAP increased serum levels of HDL and decreased serum levels of TC. CIH increases lipid delivery from the adipose tissue to the liver, up-regulates lipoprotein secretion, and delays

## Therapeutic Advances in Chronic Disease 13

Study			%
D	HDL	SMD (95% CI)	Weight
<3m			
Dorkova, Z 2008	•	-0.28 (-0.98, 0.41)	1.85
Cuhadaroğlu, C 2009		0.09 (-0.41, 0.59)	3.61
Kanimozhi, S 2015		0.01 (-0.61, 0.63)	2.33
Pan, Z 2016		-0.02 (-0.64, 0.60)	2.33
Asgari, A 2019 🗕		-0.33 (-0.80, 0.14)	4.03
Subtotal (I-squared = 0.0%, p = 0.749)	$\Leftrightarrow$	-0.11 (-0.36, 0.14)	14.16
3m~6m			
Shilna,K 2010		-0.17 (-0.56, 0.23)	5.81
Chung, S 2011		0.07 (-0.50, 0.64)	2.80
Oyama, J 2012		-0.25 (-0.75, 0.24)	3.70
Zhang, X.B 2014		-0.92 (-1.38, -0.45)	4.11
Kallianos, A 2015		-0.03 (-0.47, 0.41)	4.67
Azuma,M 2015		-0.07 (-0.49, 0.35)	5.13
Kostopoulos, K 2016		-0.18 (-0.74, 0.37)	2.91
Mineiro, M.A 2017		-0.02 (-0.49, 0.46)	3.97
Subtotal (I-squared = 39.1%, p = 0.118)	$\diamond$	-0.20 (-0.36, -0.03)	33.10
≥6m	i		
Börgel, J 2006		-0.17 (-0.47, 0.13)	10.00
Steiropoulos, P 2007		-0.06 (-0.68, 0.56)	2.33
lshida, K 2009	<del></del>	0.00 (-0.44, 0.44)	4.67
Nena, Eb 2010 ———	••••	-0.23 (-0.95, 0.48)	1.74
Nena, E 2010	• · · · ·	-0.11 (-0.51, 0.30)	5.48
Kato, M 2011	•	-0.18 (-0.69, 0.32)	3.49
Kawano, Y 2012		-0.24 (-0.75, 0.26)	3.47
Barceló, A 2014	+	-0.29 (-0.68, 0.10)	5.89
Çetin, S 2016		-0.06 (-0.59, 0.46)	3.27
Monneret, D 2016		0.07 (-0.45, 0.59)	3.27
Feliciano, A 2017	• <u>•</u>	-0.12 (-0.71, 0.48)	2.56
Feliciano, Ab 2017		0.02 (-0.55, 0.58)	2.80
Simon, B 2020		-0.38 (-0.87, 0.10)	3.78
Subtotal (I-squared = 0.0%, p = 0.993)	$\diamond$	-0.15 (-0.28, -0.02)	52.74
Overall (I-squared = 0.0%, p = 0.878)	\$	-0.16 (-0.25, -0.06)	100.00
-1.38	0	1 1.38	

Figure 7. Forest plot for HDL.

lipoprotein clearance.<sup>44</sup> CPAP effectively corrects CIH and alleviates CIH-induced hypercholesterolemia. Unlike cholesterol, TG level seems be less affected CPAP than cholesterol. A previous study<sup>45</sup> showed that reductions in serum TG levels were greater in the group with combinedintervention of CPAP and weight loss than in the group receiving CPAP only, but were not different between the combined-intervention group and the weight-loss group. Changes in LDL and HDL levels were not different among the three groups (CPAP, weight loss, or both for OSA). It is possible that serum TG levels could be easily affected by confounding factors including weight changes and diet. This reminds clinicians that interventions including weight loss and diet control should be recommended for OSA patients with hypertriglyceridemia even in participants with normal LDL-C levels.<sup>46</sup>

The results tell us the evaluation of CPAP effectiveness should be a dynamic multi-parameter periodic process. It is a must for clinicians to understand the response time of some important OSA-related parameters to treatment. Timespecific biomarker candidates according to the results could be selected as TNF- $\alpha$ , CRP, FBG, and LDL for short-term effect; HDL and TC for mid- or long-term effects of CPAP treatment. When CPAP does not work at the expected time,

Study ID	тс	SMD (95% CI)	% Weight
<3m			
Dorkova, Z 2008	•	0.66 (-0.05, 1.37)	1.69
Çuhadaroğlu, Ç 2009	•	0.49 (-0.01, 1.00)	3.34
Akinnusi, M 2011 -		0.07 (-0.40, 0.54)	3.88
Yaşar, Z.A 2014	•	0.71 (0.04, 1.39)	1.89
Guo, L.X 2015	•	0.69 (0.24, 1.14)	4.17
Kanimozhi, S 2015		-0.30 (-0.92, 0.33)	2.21
Pan, Z 2016		-0.01 (-0.63, 0.61)	2.23
Asgari, A 2019 🛛 🛶	i	-0.38 (-0.85, 0.09)	3.81
Subtotal (I-squared = 62.4%, p = 0.010)		0.23 (-0.09, 0.55)	23.22
3m~6m			
Henley, D.E 2009		0.00 (-0.72, 0.72)	1.68
Shilna,K 2010 -	•	0.03 (-0.36, 0.42)	5.50
Chung, S 2011 –		0.21 (-0.36, 0.77)	2.66
Zhang, X.B 2014		0.26 (-0.19, 0.71)	4.28
Kallianos, A 2015 —	•	0.00 (-0.44, 0.44)	4.42
Azuma,M 2015		0.18 (-0.24, 0.60)	4.84
Kostopoulos, K 2016	•	0.32 (-0.24, 0.87)	2.75
Lin, C.C 2016 —	•	0.03 (-0.44, 0.50)	3.88
Thorn, C.E 2017		• 0.17 (-0.67, 1.00)	1.23
Mineiro, M.A 2017		0.31 (-0.17, 0.79)	3.72
Subtotal (I-squared = 0.0%, p = 0.986)	$\diamond$	0.14 (-0.01, 0.30)	34.95
≥6m			
Börgel, J 2006		0.08 (-0.17, 0.33)	13.46
Steiropoulos, P 2007		- 0.44 (-0.19, 1.07)	2.18
Ishida, K 2009	•	0.46 (0.01, 0.90)	4.31
Nena, Eb 2010		0.10 (-0.61, 0.82)	1.68
Nena, E 2010	•	0.20 (-0.20, 0.61)	5.15
Kato, M 2011		-0.17 (-0.68, 0.33)	3.32
Monneret, D 2016	•	0.23 (-0.30, 0.75)	3.09
Feliciano, A 2017	•	0.21 (-0.38, 0.80)	2.44
Feliciano, Ab 2017		0.31 (-0.26, 0.88)	2.64
Simon, B 2020	•	0.46 (-0.03, 0.94)	3.57
Subtotal (I-squared = 0.0%, p = 0.726)	$\langle \diamond \rangle$	0.20 (0.05, 0.34)	41.83
Overall (I-squared = 1.6%, p = 0.441)	$  \diamondsuit$	0.18 (0.09, 0.28)	100.00
NOTE: Weights are from random effects analysis			
l -1.39	I 0	l 1.39	

Figure 8. Forest plot for TC.

combination therapy should be considered such as a healthy diet, exercise, or anti-diabetic medications or lipid-lowering drugs.

There were some limitations in this study. We included before-and-after self-controlled studies, most of which were with small sample sizes and moderate quality. Only published studies were enrolled in the analysis, which could raise the possibility of publication bias. Heterogeneity was high in some cases. Besides, we were unable to perform meta-regression for other confounding factors, including sleepiness, nadir oxygen saturation, or oxygen desaturation index, average use of CPAP every night due to the unavailable variables in many studies. In the future, high-quality research and more randomized controlled trials are necessary to give further insight into the time-dependent benefits of CPAP in OSA patients.

### Conclusion

The time-dependent profile of circulating biomarkers under CPAP treatment provides evidence for selecting phase-specific indicators for

### Therapeutic Advances in Chronic Disease 13

	SMD (95% Cl) 0.09 (-0.35, 0.52) 0.58 (-0.13, 1.28) 0.02 (-0.47, 0.52) 0.22 (-0.22, 0.66) 0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37) 0.00 (-0.72, 0.72)	Weight 3.93 1.51 3.05 3.91 1.96 1.95 3.43 19.73
	0.09 (-0.35, 0.52) 0.58 (-0.13, 1.28) 0.02 (-0.47, 0.52) 0.22 (-0.22, 0.66) 0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	3.93 1.51 3.05 3.91 1.96 1.95 3.43 19.73
	0.09 (-0.35, 0.52) 0.58 (-0.13, 1.28) 0.02 (-0.47, 0.52) 0.22 (-0.22, 0.66) 0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	3.93 1.51 3.05 3.91 1.96 1.95 3.43 19.73
	0.58 (-0.13, 1.28) 0.02 (-0.47, 0.52) 0.22 (-0.22, 0.66) 0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	1.51 3.05 3.91 1.96 1.95 3.43 19.73
	0.02 (-0.47, 0.52) 0.22 (-0.22, 0.66) 0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	3.05 3.91 1.96 1.95 3.43 19.73
	0.22 (-0.22, 0.66) 0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	3.91 1.96 1.95 3.43 19.73
	0.09 (-0.53, 0.71) 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	1.96 1.95 3.43 19.73
	- 0.28 (-0.34, 0.91) 0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	1.95 3.43 19.73
	0.16 (-0.31, 0.63) 0.17 (-0.02, 0.37)	3.43 19.73
	0.17 (-0.02, 0.37)	19.73
	0 00 (-0 72 0 72)	
	0 00 (-0 72 0 72)	
<b>•</b>	0.00 (-0.12, 0.12)	1.47
	-0.10 (-0.50, 0.29)	4.91
•	0.08 (-0.49, 0.64)	2.36
	0.14 (-0.35, 0.63)	3.14
	0.18 (-0.26, 0.63)	3.82
	0.23 (-0.21, 0.67)	3.91
	0.08(-0.34, 0.49)	4 32
	0.11 (-0.36, 0.57)	3.44
		1.07
	0.20 (-0.27, 0.68)	3 32
$\diamond$	0.11 (-0.05, 0.26)	31.75
	0.09 (-0.15, 0.34)	12.47
•	-0.06 (-0.68, 0.56)	1.97
•	0.29 (-0.15, 0.73)	3.89
	0.06 (-0.65, 0.78)	1.47
	0.04 (-0.36, 0.45)	4.62
	0.19 (-0.32, 0.69)	2.94
	0.17 (-0.34, 0.67)	2.94
	0.20(-0.19, 0.59)	4 99
	0.06 (-0.46, 0.59)	2 75
	0.27 ( 0.26, 0.79)	2.73
	0.02 ( 0.56, 0.62)	2.75
	0.05 (-0.50, 0.62)	2.10
	0.06 (-0.50, 0.63)	2.30
	-0.07 (-0.55, 0.41)	3.24
	0.11 (-0.01, 0.24)	48.52
- •	0.12 (0.03, 0.21)	100.00
		0.18 (-0.26, 0.63) 0.18 (-0.26, 0.63) 0.23 (-0.21, 0.67) 0.08 (-0.34, 0.49) 0.11 (-0.36, 0.57) 0.27 (-0.57, 1.11) 0.20 (-0.27, 0.68) 0.11 (-0.05, 0.26) 0.09 (-0.15, 0.34) -0.06 (-0.68, 0.56) 0.29 (-0.15, 0.73) 0.06 (-0.65, 0.78) 0.04 (-0.36, 0.45) 0.19 (-0.32, 0.69) 0.17 (-0.34, 0.67) 0.20 (-0.19, 0.59) 0.06 (-0.46, 0.59) 0.27 (-0.26, 0.79) 0.03 (-0.56, 0.62) 0.06 (-0.50, 0.63) -0.07 (-0.55, 0.41) 0.11 (-0.01, 0.24) 0.12 (0.03, 0.21)





Figure 10. (Continued)

journals.sagepub.com/home/taj

**Figure 10.** The time-dependent profile of the changes of CRP, TNF- $\alpha$ , FBG, FINS, LDL, HDL, TC, and TG after CPAP treatment in OSA patients. The vertical segments indicate the SMD (standardized mean difference) and its 95% CI (confidence interval). P<sub>ST</sub>, P<sub>MT</sub>, and P<sub>LT</sub> represent the *p* value of SMD for short-term [ST, <3 m (months)] mid-term (MT, 3–6 m), and long-term (LT,  $\geq 6$  m) subgroups, respectively; *p* value < 0.05, post-CPAP treatment *versus* pre-CPAP treatment. Reductions in CRP, TNF- $\alpha$ , FBG, and LDL resulting from short-term CPAP treatment, decreases in HDL and TC by mid- and long-term CPAP, and no significant change in FINS and TG at any time point.

the assessment of CPAP effectiveness, and taking comprehensive strategies besides CPAP for OSA treatment. When it comes to designing an interventional study of OSA, such as evaluation of effects of CPAP or mandibular appliance on OSA-related outcomes, a time-dependent manner should never be ignored.

### **Conflict of interest statement**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### ORCID iD

Qing Yun Li (D https://orcid.org/0000-0001-8128 -6319

### Author contributions

**Yi Wang:** Conceptualization; Formal analysis; Methodology; Supervision; Writing – original draft; Writing – review & editing.

**Ying Ni Lin:** Conceptualization; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.

**Li Yue Zhang:** Conceptualization; Investigation; Methodology; Writing – review & editing.

**Chuan Xiang Li:** Investigation; Methodology; Writing – review & editing.

**Shi Qi Li:** Investigation; Methodology; Writing – review & editing.

**Hong Peng Li:** Methodology; Writing – review & editing.

**Liu Zhang:** Formal analysis; Writing – review & editing.

**Ning Li:** Methodology; Writing – review & editing.

Ya Ru Yan: Methodology; Writing – review & editing.

**Qingyun Li:** Conceptualization; Methodology; Resources; Writing – original draft; Writing – review & editing.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the National Natural Science Foundation of China (82070089, 81700084, 81770084), National Key R&D Program of China (2018YFC1311900), and the Key Research Program of Shanghai Science and Technology Commission (18140903600).

## Supplemental material

Supplemental material for this article is available online.

### References

- Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019; 7: 687–698.
- Reutrakul S and Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. *Chest* 2017; 152: 1070–1086.
- 3. Martínez-Cerón E, Casitas R, Galera R, *et al.* Contribution of sleep characteristics to the association between obstructive sleep apnea and dyslipidemia. *Sleep Med* 2021; 84: 63–72.
- Gonzaga C, Bertolami A, Bertolami M, et al. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens 2015; 29: 705–712.
- Hariyanto TI and Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and metaanalysis. *Sleep Med* 2021; 82: 47–53.
- Kheirandish-Gozal L and Gozal D. Obstructive sleep apnea and inflammation: proof of concept based on two illustrative cytokines. *Int J Mol Sci* 2019; 20: 459.
- Hariyanto TI, Japar KV, Kwenandar F, et al. Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis. *Am J Emerg Med* 2021; 41: 110–119.

- Baessler A, Nadeem R, Harvey M, et al. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers – a meta-analysis. *J Inflamm (Lond)* 2013; 10: 13.
- Xie X, Pan L, Ren D, et al. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a metaanalysis. Sleep Med 2013; 14: 1139–1150.
- Ning Y, Zhang TS, Wen WW, et al. Effects of continuous positive airway pressure on cardiovascular biomarkers in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. *Sleep Breath* 2019; 23: 77–86.
- 11. Abud R, Salgueiro M, Drake L, *et al.* Efficacy of continuous positive airway pressure (CPAP) preventing type 2 diabetes mellitus in patients with obstructive sleep apnea hypopnea syndrome (OSAHS) and insulin resistance: a systematic review and meta-analysis. *Sleep Med* 2019; 62: 14–21.
- Iftikhar IH, Khan MF, Das A, et al. Metaanalysis: continuous positive airway pressure improves insulin resistance in patients with sleep apnea without diabetes. Ann Am Thorac Soc 2013; 10: 115–120.
- Nadeem R, Singh M, Nida M, et al. Effect of CPAP treatment for obstructive sleep apneahypopnea syndrome on lipid profile: a metaregression analysis. J Clin Sleep Med 2014; 10: 1295–1302.
- 14. Chen L, Kuang J, Pei JH, *et al.* Continuous positive airway pressure and diabetes risk in sleep apnea patients: a systemic review and meta-analysis. *Eur J Intern Med* 2017; 39: 39–50.
- 15. Xu H, Yi H, Guan J, *et al.* Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: a meta-analysis of randomized controlled trials. *Atherosclerosis* 2014; 234: 446–453.
- Lin YN, Zhou LN and Li QY. The choice of indicators for obstructive sleep apnea treatment outcome evaluation: a matter of time-dependent response? *Am J Respir Crit Care Med* 2017; 196: 1356–1357.
- 17. Mermigkis C, Bouloukaki I, Mermigkis D, et al. CRP evolution pattern in CPAP-treated obstructive sleep apnea patients. Does gender play a role? *Sleep Breath* 2012; 16: 813–819.
- 18. Simon B, Gabor B, Barta I, *et al.* Effect of 5-year continuous positive airway pressure treatment on the lipid profile of patients with obstructive

sleep apnea: a pilot study. *J Sleep Res* 2020; 29: e12874.

- 19. Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. *PLoS Med* 2009; 6: e1000097.
- Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73: 712–716.
- 21. Huizing E, Schreve MA, de Vries JPM, *et al.* Below-the-ankle angioplasty in patients with critical limb ischemia: a systematic review and meta-analysis. *J Vasc Interv Radiol* 2019; 30: 1361–1368.
- 22. Luo D, Wan X, Liu J, *et al.* Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res* 2018; 27: 1785–1805.
- 23. Wan X, Wang W, Liu J, *et al.* Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; 14: 135.
- 24. Shi J, Luo D, Wan X, *et al.* Detecting the skewness of data from the sample size and the five-number summary. *Arxiv e-prints* 2020: 2010.05749.
- 25. Jin F, Liu J, Zhang X, *et al.* Effect of continuous positive airway pressure therapy on inflammatory cytokines and atherosclerosis in patients with obstructive sleep apnea syndrome. *Mol Med Rep* 2017; 16: 6334–6339.
- Wang Y, Hu K, Liu K, *et al.* Obstructive sleep apnea exacerbates airway inflammation in patients with chronic obstructive pulmonary disease. *Sleep Med* 2015; 16: 1123–1130.
- 27. Tulmaç M, Tireli E, Ebinç H, *et al.* Effect of overnight nasal continuous positive airway pressure treatment on the endothelial function in patients with obstructive sleep apnea. *Anadolu Kardiyol Derg* 2012; 12: 560–565.
- Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. *Circulation* 2003; 107: 1129–1134.
- 29. Li Y, Chongsuvivatwong V, Geater A, *et al.* Are biomarker levels a good follow-up tool for evaluating obstructive sleep apnea syndrome treatments? *Respiration* 2008; 76: 317–323.

- Karamanlı H, Özol D, Ugur KS, et al. Influence of CPAP treatment on airway and systemic inflammation in OSAS patients. Sleep Breath 2014; 18: 251–256.
- Guo LX, Zhao X, Pan Q, et al. Effect of continuous positive airway pressure therapy on glycemic excursions and insulin sensitivity in patients with obstructive sleep apnea-hypopnea syndrome and type 2 diabetes. *Chin Med J* 2015; 128: 2301–2306.
- Gong LJ, Chang SC, Wu QH, et al. Diagnostic accuracy of the Berlin questionnaire and therapeutic effect of nasal continuous positive airway pressure in OSAHS patients with glucose metabolic dysfunction. *Sleep Breath* 2021; 25: 867–876.
- Zhang XB, Jiang XT, Lin QC, et al. Effect of continuous positive airway pressure on serum cystatin C among obstructive sleep apnea syndrome patients. Int Urol Nephrol 2014; 46: 1997–2002.
- 34. Asgari A, Soltaninejad F, Farajzadegan Z, et al. Effect of CPAP therapy on serum lipids and blood pressure in patients with obstructive sleep apnea syndrome. *Tanaffos* 2019; 18: 126–132.
- 35. Azuma M, Chihara Y, Yoshimura C, et al. Association between endothelial function (assessed on reactive hyperemia peripheral arterial tonometry) and obstructive sleep apnea, visceral fat accumulation, and serum adiponectin. *Circ J* 2015; 79: 1381–1389.
- 36. Czupryniak L, Loba J, Pawlowski M, et al. Treatment with continuous positive airway pressure may affect blood glucose levels in nondiabetic patients with obstructive sleep apnea syndrome. Sleep 2005; 28: 601–603.
- 37. Maniaci A, Iannella G, Cocuzza S, *et al.*Oxidative stress and inflammation biomarker expression in obstructive sleep apnea patients. *J Clin Med* 2021; 10: 277.

- Ryan S. Adipose tissue inflammation by intermittent hypoxia: mechanistic link between obstructive sleep apnoea and metabolic dysfunction. *J Physiol* 2017; 595: 2423–2430.
- Minoguchi K, Tazaki T, Yokoe T, *et al.* Elevated production of tumor necrosis factor-α by monocytes in patients with obstructive sleep apnea syndrome. *Chest* 2004; 126: 1473–1479.
- Ryan S, Taylor CT and McNicholas WT. Predictors of elevated nuclear factor-kappaBdependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174: 824–830.
- 41. Ünüvar Doğan F, Yosunkaya S, Kuzu Okur H, et al. Relationships between obstructive sleep apnea syndrome, continuous positive airway pressure treatment, and inflammatory cytokines. *Sleep Disord* 2014; 2014: 518920.
- 42. Dorkova Z, Petrasova D, Molcanyiova A, *et al.* Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. *Chest* 2008; 134: 686–692.
- Mokhlesi B, Grimaldi D, Beccuti G, et al. Effect of one week of CPAP treatment of obstructive sleep apnoea on 24-hour profiles of glucose, insulin and counter-regulatory hormones in type 2 diabetes. *Diabetes Obes Metab* 2017; 19: 452–456.
- 44. Adedayo AM, Olafiranye O, Smith D, et al. Obstructive sleep apnea and dyslipidemia: evidence and underlying mechanism. Sleep Breath 2014; 18: 13–18.
- 45. Chirinos JA, Gurubhagavatula I, Teff K, *et al.* CPAP, weight loss, or both for obstructive sleep apnea. *N Engl J Med* 2014; 370: 2265–2275.
- Raposeiras-Roubin S, Rosselló X, Oliva B, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021; 77: 3031–3041.

Visit SAGE journals online journals.sagepub.com/ home/taj

SAGE journals